
ImmunoVec is developing gene therapy treatments for life-threatening hematopoietic diseases.
Market:
There are over 300 life-threatening primary immune deficiencies for which there are limited treatment options currently available.Technology:
ImmunoVec has developed a platform for the generation of lentiviral vectors that are specifically engineered for each disease target. We are able to modify the patient’s own blood stem cells and introduce a highly regulated, functional copy of the gene of interest. These gene-modified blood stem cells have the ability to give rise to a fully functional immune system, without the risk of graft-versus-host disease.Advantages:
- Endogenous expression of therapeutic gene
- Optimal gene transfer
- Novel genetic elements
Development Stage:
- Pre-Clinical
Patents Issued:
- Coming Soon
Select Publications:
- Coming Soon
Contact:
Website: www.immunovec.comPortfolio Companies
- Appia Bio
- Carbonics
- CarbonBuilt
- Dalton Bioanalytics
- EarlyDx
- Electronucleics
- EP Dynamics
- Forcyte Biotechnologies
- ImmunoVec
- Lactation Lab
- Lookin, Inc.
- MyoGene Bio
- Myst Therapeutics
- Nammi Therapeutics
- NanoElectronic Imaging
- Partillion Bioscience Corporation
- Pelage Pharmaceuticals
- Pluto Immunotherapeutics
- Qwixel Therapeutics
- Restore Technologies
- Scarless Laboratories
- TrueCath
- Vault Pharma
- ViBo Health
- Westwood Bioscience
- Zenomics